Source: International Congress 2018 – Latest developments in cystic fibrosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Di Paolo (London, United Kingdom), K. Dave (London, United Kingdom), A. Vijayasingam (London, United Kingdom), R. Sheth (London, United Kingdom), E. Luke (London, United Kingdom), A. Scourfield (London, United Kingdom), L. Nwankwo (London, United Kingdom), S. Schelenz (London, United Kingdom), J. Elborn (London, United Kingdom), D. Armstrong-James (London, United Kingdom), A. Shah (London, United Kingdom). Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis. 3409

Member's Comments

No comment yet.

Related content which might interest you: Effect of microbial communities on antimicrobial drug efficacy and host inflammation in Cystic Fibrosis Source: ERS Lung Science Conference 2019 Year: 2019 Managing antimicrobial resistance in cystic fibrosis Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care Year: 2014 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018 Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005 Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006 Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Side effects of inhaled tobramycin in patients with Cystic Fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002 Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Survey of microbiology, pseudomonas eradication and antimicrobial prophylaxis in adult patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019 Antiviral activity of azithromycin in cystic fibrosis airway epithelial cells Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014 Alternating inhaled antibiotic therapy in CF: A single center analysis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF) Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012